Prudential Financial Inc. Sells 1,773,395 Shares of Elanco Animal Health Incorporated $ELAN

Prudential Financial Inc. decreased its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 30.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,956,861 shares of the company’s stock after selling 1,773,395 shares during the period. Prudential Financial Inc. owned 0.80% of Elanco Animal Health worth $56,504,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Nuveen LLC purchased a new stake in Elanco Animal Health in the 1st quarter worth $115,212,000. Dimensional Fund Advisors LP increased its holdings in shares of Elanco Animal Health by 14.3% in the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock worth $214,875,000 after purchasing an additional 2,563,740 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Elanco Animal Health by 322.0% in the second quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock worth $46,192,000 after buying an additional 2,468,122 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. purchased a new position in Elanco Animal Health during the 1st quarter valued at approximately $23,744,000. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 4.8%

Shares of NYSE ELAN opened at $22.26 on Monday. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $23.09. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The company has a market cap of $11.06 billion, a price-to-earnings ratio of 371.01, a PEG ratio of 3.02 and a beta of 1.71. The business’s 50 day moving average price is $20.87 and its 200-day moving average price is $17.11.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.13 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.Elanco Animal Health’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. On average, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on ELAN shares. UBS Group lifted their price objective on Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. KeyCorp began coverage on shares of Elanco Animal Health in a research report on Friday. They set an “overweight” rating and a $27.00 price objective for the company. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Stifel Nicolaus upped their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.56.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.